Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025
Abstract
This report provides CDC recommendations to U.S. health care providers and preparedness personnel regarding treatment and postexposure prophylaxis (PEP) of tularemia, an uncommon but potentially serious disease caused by the gram-negative coccobacillus, Francisella tularensis. Tularemia occurs naturally in the United States and other Northern Hemisphere regions. Because F. tularensis has a low infectious inoculum, it is classified as a potential bioterrorism agent that could infect thousands of persons if intentionally released, requiring rapid, informed decision-making by public health agencies, first responders, and clinicians. To mitigate the effects of a bioterrorism attack, the U.S. government stockpiles medical countermeasures, and the 21st Century Cures Act mandates development of evidence-based guidelines for their use. Since 2001 when guidelines for tularemia treatment and PEP were last published, new animal study data and human clinical data have become available. CDC compiled a broad evidence base by conducting a series of systematic reviews of the literature on human tularemia through 2023, analyzing U.S. surveillance data, gathering outbreak reports and case series, and collecting animal data. During a series of scientific forums, evidence was presented from these investigations and additional data sources to subject matter experts, and individual expert input on proposed recommendations was solicited. The guidelines team then assessed the available evidence,…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
- In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
- In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery
- Space in systems biology of signaling pathways – towards intracellular molecular crowding in silico
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.